-+ 0.00%
-+ 0.00%
-+ 0.00%

REPLIMUNE SHARES DOWN 32% AFTER FDA STAFF FLAGS BENEFIT CONCERNS ABOUT SKIN CANCER THERAPY

路透·07/28/2026 13:31:49

登錄查看新聞詳情